CEO Executive AssistantBusiness development is one of the highest-impact activities in a pharmaceutical company. Licensing deals, acquisitions, research collaborations, and co-development agreements can reshape a company’s pipeline and competitive position. They are also relationship-intensive, strategically complex, and operationally demanding.
The pharma CEO is often a critical player in business development, but that does not mean the CEO should personally manage every aspect of every deal. This framework clarifies what to delegate and what to retain.
The CEO’s Business Development Role
Strategic deal mandate. The CEO, working with the board, defines the BD strategy: which therapeutic areas, which stages of development, which deal structures, and which deal sizes align with organizational priorities and capital availability.
C-suite counterpart relationships. In major licensing negotiations or acquisition discussions, the CEO-to-CEO or CEO-to-CSO relationship is often critical. These relationships cannot be delegated.
Deal approval authority. Major licensing agreements, acquisitions above a defined threshold, and significant partnership commitments require CEO (and often board) approval.
Investor communication about deals. Announcing significant transactions, communicating deal rationale to analysts, and managing investor reactions to BD activity are CEO-level communications.
Internal alignment on deal priorities. Ensuring that scientific, clinical, commercial, and financial functions align on deal criteria and evaluation priorities requires CEO leadership.
Business Development Delegation Framework
To the Chief Business Officer or VP of Business Development
Deal sourcing and origination. Building a proprietary deal flow through industry relationships, conference networking, academic partnerships, and inbound evaluation is a BD team function.
Initial opportunity assessment. Reviewing inbound term sheets, conducting preliminary company and asset assessments, and filtering opportunities against strategic criteria are BD leadership responsibilities.
Due diligence coordination. Organizing and managing due diligence processes, coordinating cross-functional teams, tracking due diligence findings, and managing external advisors are BD operations functions.
Term sheet negotiation at the operational level. The BD team leads detailed term negotiations with appropriate legal support. The CEO engages at the strategic and final resolution level.
Partnership pipeline management. Maintaining the pipeline of ongoing BD conversations, tracking deal status, and coordinating follow-up across multiple opportunities are BD operations responsibilities.
External advisor management. Managing relationships with investment bankers, licensing advisors, and external counsel engaged in BD transactions is a BD leadership function.
Post-deal integration coordination. Managing the operational integration of acquired companies or licensed assets is a BD and operations joint function.
To the Legal Team
Agreement drafting and negotiation. License agreements, development agreements, collaboration agreements, and acquisition documentation are legal team products.
Legal due diligence. Intellectual property review, patent landscape analysis, regulatory history review, and legal liability assessment are legal due diligence functions.
Regulatory and compliance aspects of deals. Ensuring that deal structures comply with anti-corruption requirements, regulatory restrictions, and government approval requirements is a legal and compliance function.
To Finance and Corporate Development
Financial modeling and valuation. NPV modeling, deal valuation, earn-out analysis, and financial scenario planning for transactions are finance and corporate development functions.
Capital structure analysis. Assessing how transactions affect the company’s capital structure and financial position is a finance function.
Building Business Development Delegation Infrastructure
Deal Criteria Framework
A documented strategic deal criteria framework gives the BD team a filter for evaluating opportunities consistently without requiring CEO involvement in initial screening. The framework should cover: therapeutic area fit, development stage, peak sales potential, deal structure preferences, and financial hurdle rates.
BD Pipeline Dashboard
A monthly BD pipeline update covers:
- Active opportunities at each stage of evaluation
- Due diligence processes underway
- Near-term term sheet or close milestones
- Competitive intelligence on market activity
- Upcoming conference or networking priorities
The CEO reviews this dashboard to stay informed and identify where personal engagement is needed.
Deal Authority Matrix
A clear deal authority matrix documents what deal structures, financial commitments, and agreement types require CEO versus BD leadership approval. This matrix prevents BD from escalating every small decision to the CEO while ensuring the CEO’s attention on material transactions.
For pharma CEOs managing business development alongside clinical, commercial, and financial priorities, delegation framework for pharma CEO: market access strategy covers the commercial complement to business development.
Foundational delegation principles for pharmaceutical executive leadership are covered in what pharmaceutical biotech CEOs delegate to their chief of staff.
Conclusion
Business development success depends on both strong operational BD capacity and CEO engagement at the right moments. The pharma CEO who builds a capable BD function, establishes clear deal criteria and authority frameworks, and personally engages in strategic relationships and major negotiations will build a pipeline of partnerships that drives long-term organizational value.
Delegate the pipeline management. Own the relationships. Approve the strategy.
For pharmaceutical business development and licensing strategy insights, visit Forbes.com/business pharmaceutical leadership resources.
Related Reading
For further context, explore Delegation Framework for the 3PL Provider CEO and Delegation Framework for Academic Medical Center CEO.